Author

Fengzhuo Cheng

Institution: Jiangsu Hengrui Medicine (China)

Observed institutions: Peking University, Jiangsu Hengrui Medicine (China), George Institute for Global Health

ORCID: 0000-0003-1367-252X

Observed ORCID: 0000-0003-1367-252X

OpenAlex ID: A5000405171

Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial

2025 · Yanjun Xu, Kaiyan Chen, et al. · The Lancet Oncology · 41

Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial

2023 · Lili Mao, Bin Lian, et al. · JAMA Oncology · 41

First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled Trial

2025 · Yang-Si Li, Qitao Yu, et al. · Journal of Thoracic Oncology · 22

Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study

2024 · Xingxiang Pu, Gen Lin, et al. · EClinicalMedicine · 11

Sodium and Potassium Excretion of Schoolchildren and Relationship with Their Family Excretion in China

2021 · Yuan Li, Yuewen Sun, et al. · Nutrients · 8

Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies

2025 · Zhihao Lu, Guoping Sun, et al. · Cancer Immunology Immunotherapy · 6

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

2025 · Xue Hou, Chengzhi Zhou, et al. · EClinicalMedicine · 3

Road to Hierarchical Diabetes Management at Primary Care (ROADMAP) Study in China: Protocol for the Statistical Analysis of a Cluster Randomized Controlled Trial

2020 · Xian Li, Nadila Duolikun, et al. · JMIR Research Protocols · 3

Works count: 8

Citation count: 135

H-index: 6

I10-index: 4